ArticleBMC cardiovascular disorders2026
Association of insulin resistance and positive coronary artery remodeling and plaque burden in patients with acute coronary syndrome.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimPositive coronary remodeling (PR) and increased plaque burden (PB) are imaging markers of vulnerable coronary plaque. This study evaluated the association of insulin resistance (IR), assessed by the homeostasis model assessment of insulin resistance (HOMA-IR), with PR and PB in patients with acute coronary syndrome (ACS).
methodsWe retrospectively included ACS patients who underwent IVUS-guided revascularization at a single center (December 2020 to December 2021). IR positivity was defined as HOMA-IR ≥ 2.5. IVUS was used to measure external elastic membrane (EEM) and lumen areas at the target lesion and reference segments. The remodeling index (RI) was calculated as target-lesion EEM area divided by the mean EEM area of proximal and distal reference segments. PR was defined as RI > 1.05, negative remodeling as RI < 0.95, and intermediate remodeling as 0.95–1.05. PB was calculated automatically by the IVUS system as (vessel area − lumen area)/vessel area. PB and remodeling analyses were lesion-level (111 lesions from 98 patients). Logistic regression for PR used patient-clustered robust standard errors.
resultsA total of 98 ACS patients (111 target lesions) were included. Compared with the HOMA-IR-negative group, the HOMA-IR-positive group had higher PB (70.91 ± 11.49% vs 66.03 ± 13.04%, p = 0.040) and a higher RI (1.02 ± 0.32 vs 0.88 ± 0.28, p = 0.018). The HOMA-IR-positive group also showed a higher proportion of PR (43.4% vs 15.5%, p = 0.002). In the revised cluster-adjusted multivariable model (adjusted for age, sex, HbA1c, BMI, eGFR, and oral anti-diabetic drug use), HOMA-IR positivity remained independently associated with PR (adjusted OR 3.59, 95% CI 1.08–11.92, p = 0.037). ROC analysis showed modest discrimination for HOMA-IR in identifying PR (AUC 0.656, 95% CI 0.542–0.771, p = 0.0074). The exploratory Youden-optimal cutoff was 2.44 (specificity 63.3%, sensitivity 71.9%).
conclusionsHOMA-IR-defined IR positivity was independently associated with PR and higher PB in this ACS IVUS cohort. However, HOMA-IR alone showed only modest discrimination for PR and should not be interpreted as a standalone clinical predictor.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.